Your browser doesn't support javascript.
loading
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.
Lafarge, Antoine; Dupont, Thibault; Canet, Emmanuel; Moreau, Anne-Sophie; Picard, Muriel; Mokart, Djamel; Platon, Laura; Mayaux, Julien; Wallet, Florent; Issa, Nahema; Raphalen, Jean-Herlé; Pène, Frédéric; Renault, Anne; Peffault de la Tour, Régis; Récher, Christian; Chevallier, Patrice; Zafrani, Lara; Darmon, Michael; Bigé, Naike; Azoulay, Elie.
Afiliação
  • Lafarge A; Service de Médecine Intensive et Réanimation and.
  • Dupont T; Service de Médecine Intensive et Réanimation and.
  • Canet E; Service de Médecine Intensive Réanimation and.
  • Moreau AS; Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Lille, Lille, France.
  • Picard M; Réanimation, Hématologie and.
  • Mokart D; Médecine Intensive et Réanimation, Institut Paoli-Calmettes, Marseille, France.
  • Platon L; Médecine Intensive et Réanimation, Hôpital Lapeyronie, Montpellier, France.
  • Mayaux J; Médecine Intensive et Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Wallet F; Médecine Intensive et Réanimation, Hospices Civils de Lyon, Centre Hospitalier Universitaire Lyon Sud, Lyon, France.
  • Issa N; Médecine Intensive et Réanimation, Hôpital Saint-André, Bordeaux, France.
  • Raphalen JH; Médecine Intensive et Réanimation, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Pène F; Médecine Intensive et Réanimation, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Renault A; Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France; and.
  • Peffault de la Tour R; Service d'Hématologie-Greffe, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Université Paris-Cité, Paris, France.
  • Récher C; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Chevallier P; Service d'Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.
  • Zafrani L; Service de Médecine Intensive et Réanimation and.
  • Darmon M; Service de Médecine Intensive et Réanimation and.
  • Bigé N; Médecine Intensive et Réanimation, Gustave Roussy, Villejuif, France.
  • Azoulay E; Service de Médecine Intensive et Réanimation and.
Am J Respir Crit Care Med ; 210(8): 1017-1024, 2024 Oct 15.
Article em En | MEDLINE | ID: mdl-39018219
ABSTRACT
Rationale Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management.

Methods:

We investigated outcomes and determinants of mortality in a large multicenter retrospective cohort of Allo-HSCT patients admitted between January 1, 2015, and December 31, 2020, to 14 French ICUs. The primary endpoint was 90-day mortality. Measurements and Main

Results:

In total, 1,164 patients were admitted throughout the study period. At the time of ICU admission, 765 (66%) patients presented with multiple organ dysfunction, including acute respiratory failure in 40% (n = 461). The median sepsis-related organ failure assessment score was 6 (interquartile range, 4-8). Invasive mechanical ventilation, renal replacement therapy, and vasopressors were required in 438 (38%), 221 (19%), and 468 (41%) patients, respectively. ICU mortality was 26% (302 deaths). Ninety-day, 1-year, and 3-year mortality rates were 48%, 63%, and 70%, respectively. By multivariable analysis, age > 56 years (odds ratio [OR], 2.0 [95% confidence interval (CI), 1.53-2.60]; P < 0.001), time from Allo-HSCT to ICU admission between 30 and 90 days (OR, 1.68 [95% CI, 1.17-2.40]; P = 0.005), corticosteroid-refractory acute graft-versus-host disease (OR, 1.63 [95% CI, 1.38-1.93]; P < 0.001), need for vasopressors (OR, 1.9 [95% CI, 1.42-2.55]; P < 0.001), and mechanical ventilation (OR, 3.1 [95% CI, 2.29-4.18]; P < 0.001) were independently associated with 90-day mortality. In patients requiring mechanical ventilation, mortality rates ranged from 39% (no other risk factors for mortality) to 100% (four associated risk factors for mortality).

Conclusions:

Most critically ill Allo-HSCT recipients survive their ICU stays, including those requiring mechanical ventilation, with an overall 90-day survival rate reaching 51.8%. A careful assessment of goals of care is required in patients with two or more risk factors for mortality.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article